Marijuana Growth compared to HEMPI have compared the growth of Hemp Inc. with 14 other marijuana companies and they are spot on. It will be interesting to see what this year has to offer for the MJ industry.
Marijuanaindustry
BTC compared to Aphria (APH)I believe I have found a connection between Bitcoin and the MJ industry. When comparing BTC to APH I have found stunningly similar trends but Bitcoin seems top make the first move by almost a month. I have placed alphabetical reference points to show the comparison.
Since BTC seems to be ahead of APH by a month, I went ahead and placed the next trend line/target(G) based off of the most recent moves from BTC. I believe that if it follows this trend, then APH is looking at positive trend upward and a slight pullback in the month ahead.
Buy APH now and hold to target price G?
Will this trend continue in the future??
WEED confirms 3rd point on temp uptrend.As we can see, WEED keeps tapping that new upward trend line quite nicely, leaving us with a third point of confirmation on our temporary upward trend line, indicated by dotted green. This however, brings us closer to a possible ascending wedge forming. After making a significant rally today, you can see that we touched the previously drawn resistance at 33.90, pulled back and now holding as I write this. So far we have been able to keep above our EMA200 very nicely, so will most likely close on the resistance line, let's see if we can turn it into support folks!
Thanks for viewing my charts!
Cronos GroupCronos is a great test-case for what happens when a Speculative OTC stock goes to the big time market. They shot up 30% in the days after it went from OTC to the NASDAQ on some HUGE volume.
I personally like Cronos a lot. Mike Gorenstein seems like an excellent CEO and they are setting themselves up really nicely in terms of the international picture.
HOWEVER. They haven't truly DONE anything yet, at least compared to the other big names in the Canadian cannabis industry.
In their most recent financial statement, their Q3FY17 revenue was C$1.3M with a YTD revenue of C$2.5M a SMALL FRACTION of even the less-than-popular MedReleaf who had a Q3FY17 sales of C$11.35M and FY17 of C$31.6M
I guess what I am ultimately getting at is that, IMO, Cronos is grossly over valued in terms of Market Cap and I expect that to catch up to them sooner than later if they can't produce financial results on par with the rest of the industry.
I can imagine the share price breaking below the lower bounds of the triangle, falling fairly sharply to the Weekly 9EMA and potentially even correcting further.
Just my $.02
Well, That was a reLEAFAlthough there was an indication that it was going to re-test support as I mentioned, it retraced further than expected, but it respected the heavy support line drawn on the previous chart. Support remains the same, however, new support and resistance lines have also been established to indicate new windows. We closed today with a green indecision candle, so we cannot assume that it will for surely go up on Monday. If we do bounce off of this support line, we should be headed back up to where the MACD's cross resistance. If it drops down below, we may see a re-test as low as 18.00, but hopefully the bulls catch at 18.35.
ADVT looking bullish...thank Canadian bears & compliance lawsWhat do you guys think?
I say it breaks out based off the increase in volume, and the fact that the Canadian markets haven't affected ADVT. Why? They're based in Newport Beach, California.
Here's some fluff:
globenewswire.com
Also my thoughts in general:
-ADVT looks like a solid company from the top down with expansion in mind, a 2018 projected exponential increase of earnings, and new orders
-Ancillary companies will benefit from cannabis industry without the risk of dropping cannabis prices
-The compliance (ie, packaging) industry will be substantial because as states or countries legalize, compliance laws go into effect (opaque, child proof, etc), companies like ADVT are necessary.
www.leafly.com
-Ancillary companies aren't bound by state borders like cannabis producers
-Companies first in to secure contracts to big producers, have money behind them, and will likely be the biggest in that industry niche
-Canadian marijuana stock sellers in search for those crazy returns after the Canadian cannabis market started consolidating after that insane bull run.
-US Cannabis market is volatile but cheap, so a mass of people are looking for cheap stocks with growth potential
I guess we'll see.
I'm going long.
ProjeXions Series - Vol1 - Cannabis Industry - CBIS, 2-YEAR, OTCThis is a work-flow experiment. The details surrounding the indicators and metrics used to arrive at my conclusions will be discussed when my targets are met.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
ProjeXions Series - Vol1 - Cannabis Industry - NDEV, 3-YEAR, OTCThis is a work-flow experiment. The details surrounding the indicators and metrics used to arrive at my conclusions will be discussed if & when my targets are met. Some data factors used: trend lines, E.Waves, channels, fibs, MA, RSI etc.
Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has developed its infrastructure within many lines of the insurance business such as, health, property & casualty, life, accident and fixed annuities.
Novus medical cannabis benefits package will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient.
The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.
$THC // Getting higherTHC / Hemp Coin has a rebranding, a hard fork, and a conference all coming up in the next week. If it's all positive then we could see this light up and get higher.
MYMMF pennant breakout with gap up confirmationMYMMF canadian cannabis company made a small breakout yesterday evening shown by my previous graph yesterday. This morning full confirmation breakout, it gaped up on relatively higher volume through heavy resistance at 2.8$ resistance. Here would be good entry for a run up, this stock might test new all time highs in the coming weeks.
This marijuana stock will keep losing money I like cannabis stocks, have been bullish on the sector for the last year. I don't think 2018 will be any different. However i don't like the company aurora cannabis from a fundamental point of view. The company has not been able to turn a profit, the massive run up in stockprice is based on future expectations. If the company is now not able to turn a profit, how will they be in the future when margins only will erode over time? Management is incompetent, the last Cannimed deal shows how irresponsibly they allocate capital. It would not surprise me to see this stock drop -50% over the next year. Be warned.
